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Abstract. Background/Aim: Tolerability and safety of
trastuzumab emtansine (T-DM1) was investigated in Japanese
patients with HER2-positive advanced breast cancer who were
previously treated with chemotherapy and trastuzumab. Patients
and Methods: Patients with inoperable or recurrent breast
cancer who were previously treated with chemotherapy and
trastuzumab in adjuvant and/or metastatic disease were
included. T-DM1 3.6 mg/kg was administered intravenously
every 21 days. The administration dosage or schedule of T-DM1
was modified based on laboratory tests on the administration
day. Results: Among 232 patients analyzed, adverse events were
reported in 228 patients (98.3%); five patients (2.2%)
discontinued due to adverse events and twenty patients (8.6%)
had serious adverse events. The most commonly reported 
grade ≥3 adverse event of special interest was thrombocytopenia
(69 patients; 29.7%), followed by hepatotoxicity (26 patients;
11.2%). Conclusion: T-DM1 was well tolerated in Japanese
patients with HER2-positive advanced breast cancer and no new
safety signals were observed.
The human epidermal growth factor receptor 2 (HER2) has
been shown to play an important role in the development and
progression of certain types of breast cancer. HER2 is
overexpressed in ~20% of patients with breast cancer and is
associated with a more aggressive tumor growth and poor
clinical outcome (1-3). Since trastuzumab, an anti-HER2
humanized monoclonal antibody, demonstrated the significant
survival benefit in patients with HER2-positive metastatic breast
cancer (4), combination of anti-HER2 therapy with standard
chemotherapy has been used as an effective therapeutic
approach for patients with HER2-positive advanced breast
cancer. In addition, dual blockade of HER2 with combination
of pertuzumab and trastuzumab plus chemotherapy showed
significant improvement in overall survival compared to
trastuzumab plus chemotherapy (5). To date, several novel anti-
HER2 therapeutic agents, including trastuzumab, lapatinib,
pertuzumab, and trastuzumab emtansine, have been developed.
Trastuzumab emtansine, known as T-DM1, is an antibody
drug conjugate incorporating trastuzumab with microtubule-
inhibitory agent DM1 (derivative of maytansine); the anti-
HER2 antibody and cytotoxic agent are conjugated via a
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stable linker (6, 7). T-DM1 is designed to deliver the
cytotoxic agent specifically to HER2-positive cells, that may
improve the clinical benefits of anticancer therapy of
trastuzumab with DM1 and minimize the exposure to normal
tissues. Phase III study (EMILIA) demonstrated that T-DM1
significantly prolonged progression-free and overall survival
with a more favorable safety profile than lapatinib plus
capecitabine in patients with HER2-positive advanced breast
cancer who were previously treated with trastuzumab and
taxane (8). Another phase III study (TH3RESA) demonstrated
that T-DM1 prolonged progression-free and showed survival
benefit with less high-grade toxicity compared to a treatment
of physician’s choice in patients with HER2-positive
advanced breast cancer who were previously treated with
both trastuzumab and lapatinib in the advanced setting and a
taxane in any setting, and had disease progression after at
least two regimens of HER2-directed therapy (9).
In Japan, T-DM1 was approved with the recommended
dose of 3.6 mg/kg given as an intravenous infusion every 3
weeks according to the results of clinical studies conducted
in Japan (10, 11). The most common grade 3/4 adverse
events of T-DM1 include thrombocytopenia, and
hepatotoxicity (including nodular regenerative hyperplasia,
aspartate aminotransferase [AST] increased and/or alanine
aminotransferase [ALT] increased) (10). The incidence of
grade 3/4 thrombocytopenia (22%) and AST/ALT increased
(14%/8%) in Japanese patients (10) tends to be higher than
Western population (grade ≥3 thrombocytopenia, 4.7% to
12.9%; grade ≥3 AST increased, <2% to 6.0%, grade ≥3 ALT
increased <2% to 2.9%) (8, 9, 12, 13). As further evaluation
of safety of T-DM1 in Japanese patients is valuable, we
conducted another phase II study (JO29317) to investigate
the tolerability and safety, including the incidence of distinct
adverse events of T-DM1 in Japanese patients with pre-
treated HER2-positive advanced breast cancer under the
settings that were similar to routine clinical practice.
Patients and Methods
Patients. Eligible patients had inoperable or recurrent breast cancer
and were previously treated with chemotherapy and trastuzumab in
adjuvant and/or metastatic disease. Inclusion criteria were age of ≥20
years, and confirmed HER2-positive status by immunohistochemical
analysis (with 3+ indicating positive status), fluorescence in situ
hybridization (with an amplification ratio ≥2.0 indicating positive
status), or both. Patients with Eastern Cooperative Oncology Group
performance status of 0-3 were also included. Additional eligibility
criteria included adequate bone marrow, hepatic and renal function,
as defined by the laboratory tests including platelet count ≥75,000/μl,
total bilirubin levels ≤1.5 × the upper limit of normal, and AST/ALT
levels ≤5 × the upper limit of normal.
Major exclusion criteria included prior treatment with T-DM1,
having experienced a serious hypersensitive reaction to trastuzumab,
left ventricular ejection fraction (LVEF) of less than 45% at baseline,
a history of serious cardiac disease or dysfunction, central nervous
system metastases, and peripheral neuropathy of grade 3 or higher
(according to the National Cancer Institute Common Terminology
Criteria for Adverse Events [CTCAE] version 4.03, Japanese version). 
Study design and measures. The present phase II study is a single
arm, multi-center study, conducted between December 2013 and
August 2014. The study protocol and all amendments were
approved by local Ethic Committees or the institutional review
board at each study site. This study was conducted in accordance
with the Good Clinical Practice guidelines and the Declaration of
Helsinki, as well as other applicable regulatory requirements. All
study participants provided written informed consent prior to study
entry. The present study has been registered with the Japan
Pharmaceutical Information Center (ID: JapicCTI-132395,
registered on December 26, 2013).
Patients received a starting dose of 3.6 mg/kg T-DM1
intravenously every 21 days and were followed up until the 28th day
after the last dose of T-DM1. Administration of T-DM1 was based
on the criteria of dose modification; the first step of dose reduction
was to 3.0 mg/kg, and the second step was to 2.4 mg/kg; the next
step was discontinuation of T-DM1 therapy. Dose escalation was not
allowed after a dose reduction. T-DM1 was administered for at least
3 cycles; therapy was continued until the development of
unmanageable toxicity, death, or withdrawal of consent. The study
continued until T-DM1 became available for clinical practice at the
study site. The administration dosage or schedule of T-DM1 was
modified based on platelet count, AST/ALT levels, or total bilirubin
levels on the administration day based on the consideration of the
abnormal values of platelet count and AST/ALT levels on day 8 of
each cycle tended to normalize on the day 1 of the next cycle (14).
The administration of T-DM1 was discontinued due to grade 4
AST/ALT increased, grade 2 AST/ALT increased and total bilirubin
levels >2 × the upper limit of normal, grade 4 total bilirubin
increased, nodular regenerative hyperplasia, or grade ≥3
hypersensitivity/infusion reaction, while it was ceased due to grade
3/4 thrombocytopenia, grade 3 AST/ALT increased, grade 2/3 total
bilirubin increased, or grade 3/4 peripheral neuropathy. 
The primary outcome of the present study was safety; the
incidence of selected adverse events of special interest included
thrombocytopenia, hepatotoxicity, peripheral neuropathy,
hypersensitivity/infusion reaction, pneumonitis, and cardiac
dysfunction. The secondary outcome included the incidence of overall
adverse events (any untoward or unfavorable medical occurrence) and
serious adverse events (any adverse event that results in death, is life
threatening, requires or prolongs hospitalization, causes persistent or
significant disability or incapacity), and changes in laboratory tests
and vital signs. In addition, subgroup analyses were performed.
Modification of administration dosage and schedule of T-DM1 was
based on laboratory values on day 8 of cycle 1 in the previous phase
II study JO22997 in Japan (10). However, in this study, patients were
permitted to receive full dose of T-DM1 on day 1 of cycle 2 according
to the laboratory values on that day; tolerability was also evaluated
in these patients even though they met criteria for modification of
administration dosage and schedule of T-DM1 stated in the JO22997
study. Furthermore, the relationship between the severity of
thrombocytopenia and haemorrhage was analyzed.
Information on the baseline of patients characteristics, including
age, HER2 and hormone receptor status, hepatic function,
haematological information, vital signs, medical history, sites of
metastases, and physical condition, were collected at baseline. The
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LVEF was measured with echocardiography or multiple-gated
acquisition scanning before study entry and every 4 cycles thereafter.
Information on the laboratory and haematological test values were
collected on days 1, 8, and 22 of cycles 1-3, day 1 of cycle 4 and
thereafter, and an additional assessment was performed 28 days after
the last dose of T-DM1. Vital signs and physical examination
findings were also assessed on regular basis. All adverse events were
monitored continuously and were coded using the Japanese version
of the Medical Dictionary for Regulatory Activities (MedDRA/J)
version 16.1 System Organ Class and Preferred Term, and were
graded according to the CTCAE version 4.03.
Analytical methods. This study was an exploratory study with an
enrollment target of approximately 250 patients. The primary
analyses of safety included all enrolled patients who received at
least one dose of T-DM1. Continuous measurements were
summarized by mean or median, and categorical data were
summarized by frequency or percentages.
Results
Patients. A total of 234 patients were enrolled at 68 sites in
Japan between December 19, 2013 and April 25, 2014, and
the last follow-up was performed in August 7, 2014. Among
those enrolled in this study, 232 patients received at least one
dose of T-DM1 (safety population). During the study period,
all 232 patients in the safety population discontinued the
study (Figure 1). The majority of them (166 patients; 71.6%)
discontinued the study and continued treatment in routine
clinical practice after T-DM1 became available on the market
in Japan. Among the safety population, the median age was
57.0 years (range=20-87 years), median number of prior
chemotherapy regimens for advanced disease was 3
(range=1-15). T-DM1 was administered for a median of 3
doses (range=1-9) (Table I).
Primary outcome. The adverse events of special interest are
summarized in Table II. The most commonly reported
adverse event of special interest of any grade was
thrombocytopenia (162 patients; 69.8%), followed by
hepatotoxicity (140 patients; 60.3%) and peripheral
neuropathy (18 patients; 7.8%). The most commonly
reported grade ≥3 adverse event of special interest was
thrombocytopenia (69 patients; 29.7%), followed by
hepatotoxicity (26 patients; 11.2%). NRH was not reported
in any patients during the study. LVEF <40% was reported
in 1 patient; the LVEF was decreased from 54% at baseline
to 30% after the third dose of T-DM1.
Secondary outcome. Overview of adverse events is
summarized in Table III. Adverse events were reported in 228
patients (98.3%), grade ≥3 adverse events were reported in
109 patients (47.0%), and serious adverse events were
reported in 20 patients (8.6%); no patients died due to adverse
events. Overall, the most reported adverse event of any grade
was thrombocytopenia (162 patients; 69.8%), followed by
AST increased (105 patients; 45.3%), ALT increased (68
patients; 29.3%), and nausea (58 patients; 25.0%). The most
reported grade ≥3 adverse event was thrombocytopenia (69
patients; 29.7%), followed by AST increased (12 patients;
5.2%) and hepatic function abnormal (12 patients; 5.2%). The
most reported serious adverse events (reported in at least 2
patients) were nausea (3 patients; 1.3%) and pyrexia (3
patients; 1.3%), followed by malaise (2 patients; 0.9%),
hepatic function abnormal (2 patients; 0.9%) and anemia (2
patients; 0.9%). Adverse events leading to discontinuation of
T-DM1 administration—congestive heart failure, ventricular
fibrillation, cellulitis, pneumonitis, and haemorrhagic
cystitis—were reported in 5 patients (2.2%). A total of 9
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Figure 1. Patient disposition.
patients required dose modification of T-DM1; the most
common adverse event requiring dose modification was
decreased platelet count (6 patients; 2.6%). The mean
changes in platelet count and levels of AST and ALT among
the safety population are shown in Figure 2. During cycles 1-
3, the platelet count transiently decreased on day 8 of each
cycle (Figure 2A), while AST levels were transiently
increased on day 8 of each cycle (Figure 2B) and ALT levels
were transiently increased on day 8 of cycle 1 (Figure 2C).
The platelet count reached nadir and AST/ALT levels reached
a peak with the largest fluctuation range on day 8 of cycle 1.
in vivo 31: 493-500 (2017)
496
Table I. Baseline characteristics and trastuzumab emtansine exposure
among the safety population.
                                                                                  Total (N=232)
Age, years                                                                             
    Median                                                                          57.0
    Range                                                                           20-87
ECOG PS, n (%)                                                                           
    0                                                                            165          (71.1)
    1                                                                              64          (27.6)
    2                                                                                3           (1.3)
    3                                                                                0             (0)
Hormone receptor status, n (%)                                                   
    ER–/PgR–                                                             109          (47.0)
    ER–/PgR+                                                                 5           (2.2)
    ER+/PgR–                                                               46          (19.8)
    ER+/PgR+                                                               68          (29.3)
    ER+/PgR unknown                                                  2           (0.9)
    ER unknown/PgR+                                                  1           (0.4)
    Both unknown                                                          1           (0.4)
Number of chemotherapy regiments
for advanced disease                                                                     
    Median                                                                             3
    Range                                                                            1-15
Number of T-DM1 doses administered                               
    Median                                                                             3
    Range                                                                             1-9
Treatment duration of T-DM1, weeks                                 
    Median                                                                           7.0
    Range                                                                         0.1-24.3
ECOG PS, Eastern Cooperative Oncology Group Performance Status;
ER, estrogen receptor; PgR, progesterone receptor; T-DM1, trastuzumab
emtansine.
Table II. Adverse events of special interest.
                                                                               Total (N=232)
                                                             Any grade      Grade 3      Grade 4
                                                              No        %      No      %     No    %
Thrombocytopenia                               162     69.8     60     25.9    9     3.9
Hepatotoxicity                                     140     60.3     25     10.8    1     0.4
Peripheral neuropathy                          18       7.8       1       0.4     0       0
Hypersensitivity/infusion reaction        4        1.7       0        0       0       0
Pneumonitis                                           3        1.3       1       0.4     0       0
Cardiac dysfunction                              1        0.4       1       0.4     0       0
Adverse events of special interest included thrombocytopenia,
hepatotoxicity, peripheral neuropathy, hypersensitivity/infusion reaction,
pneumonitis, and cardiac dysfunction were assessed. The items included
all related preferred terms of adverse events.
Table III. Overview of adverse events.
                                                                                      Total (N=232)
                                                                       Number of patients      %
Any grade adverse events                                         228                  98.3
   Any grade adverse events reported 
   >15% of patients                                                                                
       Thrombocytopenia                                             162                  69.8
       AST increased                                                    105                  45.3
       ALT increased                                                      68                  29.3
       Nausea                                                                  58                  25.0
       Malaise                                                                 57                  24.6
       Pyrexia                                                                  57                  24.6
       Epistaxis                                                               55                  23.7
       Decreased appetite                                               46                  19.8
       Hepatic function abnormal                                  31                  13.4
Grade ≥3 adverse events                                           109                  47.0
   Grade ≥3 adverse events reported 
   >2% of patients                                                                                  
       Thrombocytopenia                                               69                  29.7
       AST increased                                                      12                    5.2
       Hepatic function abnormal                                  12                    5.2
Serious adverse events                                                20                    8.6
   Serious adverse events reported
   in at least 2 patients                                                                          
       Nausea                                                                    3                    1.3
       Pyrexia                                                                    3                    1.3
       Malaise                                                                   2                    0.9
       Hepatic function abnormal                                    2                    0.9
       Anemia                                                                   2                    0.9
Adverse events leading to treatment 
discontinuation                                                              5                    2.2
       Congestive heart failure                                        1                    0.4
       Ventricular fibrillation                                           1                    0.4
       Cellulitis                                                                 1                    0.4
       Pneumonitis                                                            1                    0.4
       Haemorrhagic cystitis                                            1                    0.4
Adverse events leading to dose 
modification                                                                  9                    3.9
       Decreased platelet count                                        6                    2.6
       Anemia                                                                   1                    0.4
       Diarrhea                                                                  1                    0.4
       Hepatic function abnormal                                    1                    0.4
       Decreased appetite                                                 1                    0.4
       Fatigue                                                                    1                    0.4
       Epistaxis                                                                 1                    0.4
Adverse events leading to death                                  0                    0
Exploratory analyses. Grade 4 thrombocytopenia was
reported in 9 patients on day 8 of cycle 1. Among them, 7
were permitted to receive T-DM1 with no dose reduction
in cycle 2. In 1 patient (shown by a black line in Figure
3A), the platelet count decreased more on day 8 of cycle
2 than on day 8 of cycle 1. Grade ≥3 AST increased was
reported in 23 patients on day 8 of cycle 1; 15 of these
patients were permitted to receive T-DM1 with no dose
reduction in cycle 2. In 1 patient (shown by a black line in
Figure 3B), AST level increased after day 1 of cycle 1.
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Figure 2. Changes in platelet count and levels of AST and ALT among
the safety population (N=232). (A) Changes in platelet count, (B)
changes in AST, and (C) changes in ALT.
Grade ≥3 ALT increased was reported in 4 patients on day
8 of cycle 1; however, all 4 of these patients were
permitted to receive T-DM1 with no dose reduction in
cycle 2. The ALT level was transiently increased on day 8
of each cycle (Figure 3C).
To explore the relationship between the severity of
thrombocytopenia and haemorrhage, the incidence of those
adverse events by grade were cross-tabulated (Table IV).
Among 77 patients who had grade 3/4 thrombocytopenia,
only 1 patient (1.3%) experienced grade 4 haemorrhage. In
this patient, the grade 4 thrombocytopenia was reported on
day 8 of cycle 1, while grade 4 haemorrhage
(haemorrhagic cystitis) was reported on day 21 of cycle 2
(platelet count of this patient was >300×109/L on day 1 of
cycle 3, measured soon after the incidence of grade 4
haemorrhage).
in vivo 31: 493-500 (2017)
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Figure 3. Changes in platelet count and levels of AST and ALT among
patients who were permitted to receive full dose of T-DM1 (3.6 kg/kg)
on day 1 of cycle 2, even though these patients had met criteria for
modification of administration dosage and schedule of T-DM1 stated in
the previously conducted phase II study JO22997. (A) Platelet count in
patients who had thrombocytopenia of grade ≥4 on day 8 of cycle 1 and
grade ≤2 on day 1 of cycle 2 (n=7). (B) AST levels in patients who had
AST increased of grade ≥3 on day 8 of cycle 1 and grade ≤2 on day 1
of cycle 2 (n=15). (C) ALT levels in patients who had ALT increased of
grade ≥3 on day 8 of cycle 1 and grade ≤2 on day 1 of cycle 2 (n=4).
Discussion
The present phase II study was conducted to evaluate the
safety of T-DM1 in Japanese patients with previously treated
HER2-positive advanced breast cancer under real-world
settings. The administration of T-DM1 was modified
according to the laboratory values on day 1 of each cycle.
There were no patients who discontinued T-DM1 therapy due
to thrombocytopenia or AST/ALT increased. Adverse events
of any grade were reported in most patients (98.3%); all
reported adverse events were expected and no new adverse
events were reported.
The methods of administration dosage or schedule
modification of T-DM1 varied between the previous phase II
study JO22997 (10) and the present study. In JO22997, the
administration dosage or schedule of T-DM1 was modified
based on the laboratory values during any time point in the
study period because the most abnormal laboratory values
during the cycle was considered to be critical for safety. On
the other hand, in the present study, the administration
dosage or schedule of T-DM1 was modified according to the
laboratory values on the administration day based on the
pooled safety analysis data (14). Adverse events were
reported in 228 patients (98.3%), but only 5 patients (2.2%)
discontinued T-DM1; thus, T-DM1 was considered to be well
tolerated, with the caveat that the median number of T-DM1
cycles was only 3 in the present study. The incidence and
severity of thrombocytopenia observed in the present study
were comparable to those in JO22997 (10). The incidence of
grade ≥3 thrombocytopenia was 29.7% in the present study
compared to 22% in JO22997. In the present study, grade ≥3
AST/ALT increased was 5.2% and 1.3%, respectively,
compared to 14% and 8%, respectively, in JO22997.
In this study, the platelet count tended to decrease while the
AST/ALT levels tended to increase on day 8 of each cycle and
sufficiently recovered to allow continuation of T-DM1 on day
1 of the next cycle. A similar pattern was observed in non-
Japanese populations (14). According to the laboratory tests
on day 1 of cycle 2, 7 patients who had grade ≥4
thrombocytopenia, 15 patients who had grade ≥3 AST
increased, and 4 patients who had grade ≥3 ALT increased on
day 8 of cycle 1 were permitted to receive full dose of T-DM1
on day 1 of cycle 2. Although the platelet count, as well as
AST/ALT levels, might not have been fully reversible to
baseline levels in some patients, they could be recovered to
allow continuation of T-DM1 administration. Our investigation
on the relationship between incidence of thrombocytopenia
and haemorrhage revealed limited association of grade 3/4
thrombocytopenia with grade 3/4 haemorrhage. That is, of the
77 patients who had grade 3/4 thrombocytopenia, only 1
patient (1.3%) experienced grade 4 haemorrhage; in this
patient, the grade 4 haemorrhagic event was observed
approximately five weeks after grade 4 thrombocytopenia was
reported – when the platelet count recovered to the normal
level. Thus, the incidence of grade 4 thrombocytopenia was
not considered to be associated with grade 4 haemorrhagic
event in this patient. A similar pattern was observed in non-
Japanese populations. The recently reported pooled safety
analysis demonstrated that grade 3/4 thrombocytopenia was
rarely associated with grade 3/4 haemorrhage; the proportion
of patients who had both grade 3/4 thrombocytopenia and
grade 3/4 haemorrhage was 0.67% (6 of 884 patients) (14). 
There are some limitations for this study and caution is
needed in the interpretation of the results. The present study
was exploratory to investigate the safety of T-DM1, without
any comparisons. Furthermore, the median number of cycles
was relatively small.
In conclusion, our safety analyses demonstrated that T-DM1
was well tolerated within the early phase of T-DM1 therapy
in Japanese patients with HER2-positive advanced breast
cancer who were previously treated with a trastuzumab-
containing regimen. No new safety signals were observed.
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Table IV. Cross-tabulation of platelet count and haemorrhage.
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